Publications by authors named "Ali Khanehzar"
Article Synopsis
- The alternative pathway of the complement system is linked to age-related macular degeneration (AMD), with current FDA-approved treatments showing potential risks that highlight the need for safer options.
- Researchers have found that Poly Sialic acid nanoparticles (PolySia-NP) can inhibit the alternative complement pathway and enhance the binding of complement factor H (CFH), potentially offering safer therapeutic benefits.
- PolySia-NP treatment not only suppresses harmful complement activity and inflammatory responses in various models but also reduces neovascularization, presenting a promising alternative to existing AMD treatments.
An inflammation-resolving polysialic acid-decorated PLGA nanoparticle (PolySia-NP) has been developed to treat geographic atrophy/age-related macular degeneration and other conditions caused by macrophage and complement over-activation. While PolySia-NPs have demonstrated pre-clinical efficacy, this study evaluated its systemic and intraocular safety. PolySia-NPs were evaluated in vitro for mutagenic activity using strains and , with and without metabolic activation; cytotoxicity was evaluated based on its interference with normal mitosis.
View Article and Find Full Text PDFIn addition to the intrinsic toxicity associated with the chemical composition of nanoparticles (NP) and their ligands, biofunctionalized NP can perturb specific cellular processes through NP-cell interactions and induce programmed cell death (apoptosis). In the case of the epidermal growth factor (EGF), nanoconjugation has been shown to enhance the apoptotic efficacy of the ligand, but the critical aspects of the underlying mechanism and its dependence on the NP morphology remain unclear. In this manuscript we characterize the apoptotic efficacy of nanoconjugated EGF as a function of NP size (with sphere diameters in the range 20-80 nm), aspect ratio (A.
View Article and Find Full Text PDF